Vascular access devices in pediatric oncology

"TIVADs may be prioritized for pediatric chemotherapy when feasible, taking into account factors such as cost, provider expertise, and patient preference" Liu et al (2025).

"TIVADs may be prioritized for pediatric chemotherapy when feasible, taking into account factors such as cost, provider expertise, and patient preference" Liu et al (2025).

ReTweet

Vascular access devices in pediatric oncology

Highlights:

In pediatric oncology patients, there is limited evidence to guide central venous access device selection.

TIVADs reduce key adverse events in pediatric oncology: compared to tunneled CVCs, TIVADs significantly lower risks of systemic infection, mechanical failure, and premature device removal, favoring their use for long-term chemotherapy access.

TIVADs may be prioritized for pediatric chemotherapy when feasible, taking into account factors such as cost, provider expertise, and patient preference.

Reference:

Liu C, Yang D, Guo X, Wang J, Wang R, Qu H, Liu L. Adverse Events of Tunneled Central Venous Catheters versus Totally Implantable Venous Access Devices in Pediatric Oncology: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol. 2025 Jun 21:S1051-0443(25)00416-6. doi: 10.1016/j.jvir.2025.06.008. Epub ahead of print. PMID: 40550455.